News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,978 Results
Type
Article (43337)
Company Profile (271)
Press Release (691359)
Multimedia
Podcasts (124)
Webinars (22)
Section
Business (207069)
Career Advice (2114)
Deals (35831)
Drug Delivery (135)
Drug Development (82606)
Employer Resources (174)
FDA (16748)
Job Trends (15240)
News (351119)
Policy (33759)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2656)
Accelerated approval (39)
Adcomms (28)
Allergies (159)
Alliances (50338)
ALS (191)
Alzheimer's disease (1761)
Antibody-drug conjugate (ADC) (367)
Approvals (17018)
Artificial intelligence (582)
Autoimmune disease (211)
Automation (46)
Bankruptcy (367)
Best Places to Work (11771)
BIOSECURE Act (21)
Biosimilars (200)
Biotechnology (176)
Bladder cancer (175)
Brain cancer (62)
Breast cancer (681)
Cancer (5243)
Cardiovascular disease (447)
Career advice (1790)
Career pathing (40)
CAR-T (299)
CDC (54)
Celiac Disease (2)
Cell therapy (800)
Cervical cancer (41)
Clinical research (70842)
Collaboration (1868)
Company closure (4)
Compensation (1239)
Complete response letters (74)
COVID-19 (2788)
CRISPR (101)
C-suite (944)
Cystic fibrosis (147)
Data (6810)
Decentralized trials (2)
Denatured (28)
Depression (154)
Diabetes (563)
Diagnostics (6858)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (281)
Drug pricing (216)
Drug shortages (33)
Duchenne muscular dystrophy (270)
Earnings (91445)
Editorial (63)
Employer branding (22)
Employer resources (153)
Events (119469)
Executive appointments (1026)
FDA (20091)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1580)
Gene editing (216)
Generative AI (49)
Gene therapy (666)
GLP-1 (1131)
Government (5056)
Grass and pollen (7)
Guidances (390)
Healthcare (19254)
HIV (72)
Huntington's disease (52)
IgA nephropathy (88)
Immunology and inflammation (277)
Immuno-oncology (79)
Indications (147)
Infectious disease (3101)
Inflammatory bowel disease (204)
Inflation Reduction Act (15)
Influenza (128)
Intellectual property (270)
Interviews (341)
IPO (16732)
IRA (52)
Job creations (3797)
Job search strategy (1488)
JPM (64)
Kidney cancer (18)
Labor market (91)
Layoffs (577)
Leadership (37)
Legal (8142)
Liver cancer (96)
Longevity (25)
Lung cancer (702)
Lymphoma (398)
Machine learning (53)
Management (59)
Manufacturing (903)
MASH (182)
Medical device (14027)
Medtech (14100)
Mergers & acquisitions (20217)
Metabolic disorders (1498)
mRNA (175)
Multiple sclerosis (175)
NASH (23)
Neurodegenerative disease (384)
Neuropsychiatric disorders (96)
Neuroscience (3141)
Neurotech (1)
NextGen: Class of 2026 (6649)
Non-profit (4633)
Now hiring (73)
Obesity (736)
Opinion (293)
Ovarian cancer (176)
Pain (227)
Pancreatic cancer (248)
Parkinson's disease (330)
Partnered (33)
Patents (540)
Patient recruitment (558)
Peanut (62)
People (59752)
Pharmaceutical (62)
Pharmacy benefit managers (32)
Phase 1 (22036)
Phase 2 (31134)
Phase 3 (23310)
Pipeline (6533)
Policy (318)
Postmarket research (2618)
Preclinical (9380)
Press Release (67)
Prostate cancer (268)
Psychedelics (54)
Radiopharmaceuticals (297)
Rare diseases (974)
Real estate (6029)
Recruiting (71)
Regulatory (25399)
Reports (54)
Research institute (2453)
Resumes & cover letters (363)
Rett syndrome (32)
RNA editing (17)
RSV (87)
Schizophrenia (157)
Series A (263)
Series B (197)
Service/supplier (12)
Sickle cell disease (106)
Special edition (25)
Spinal muscular atrophy (164)
Sponsored (44)
Startups (3677)
State (2)
Stomach cancer (20)
Supply chain (119)
Tariffs (96)
The Weekly (94)
Vaccines (1076)
Venture capital (94)
Weight loss (500)
Women's health (108)
Worklife (19)
Date
Today (137)
Last 7 days (597)
Last 30 days (3102)
Last 365 days (30327)
2026 (6721)
2025 (30548)
2024 (35608)
2023 (40443)
2022 (51623)
2021 (56260)
2020 (54757)
2019 (47414)
2018 (35723)
2017 (32581)
2016 (32089)
2015 (38127)
2014 (31806)
2013 (26776)
2012 (28973)
2011 (29659)
2010 (27723)
Location
Africa (774)
Alabama (87)
Alaska (7)
Arizona (328)
Arkansas (13)
Asia (40038)
Australia (6616)
California (12044)
Canada (3483)
China (1191)
Colorado (510)
Connecticut (516)
Delaware (356)
Europe (86890)
Florida (1814)
Georgia (382)
Hawaii (3)
Idaho (63)
Illinois (937)
India (76)
Indiana (559)
Iowa (22)
Japan (468)
Kansas (130)
Kentucky (44)
Louisiana (34)
Maine (73)
Maryland (1466)
Massachusetts (8644)
Michigan (341)
Minnesota (659)
Mississippi (7)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (131)
New Hampshire (84)
New Jersey (3189)
New Mexico (28)
New York (3168)
North Carolina (1538)
North Dakota (9)
Northern California (5938)
Ohio (357)
Oklahoma (21)
Oregon (41)
Pennsylvania (2424)
Puerto Rico (25)
Rhode Island (50)
South America (1142)
South Carolina (72)
South Dakota (1)
Southern California (4714)
Tennessee (196)
Texas (1871)
United States (42674)
Utah (361)
Vermont (1)
Virginia (286)
Washington D.C. (83)
Washington State (966)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
734,978 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
March 11, 2026
·
2 min read
·
Tristan Manalac
Diabetes
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data
Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.
March 19, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
December 18, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
·
1 min read
·
Jef Akst
Earnings
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales
While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established itself as the clear leader in the obesity market, in the process capturing investors’ attention and enthusiasm.
March 18, 2026
·
8 min read
·
Tristan Manalac
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
·
2 min read
·
Tristan Manalac
Editorial
Novo Will Never Beat Lilly. Why Does It Have To?
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
February 5, 2026
·
3 min read
·
Annalee Armstrong
1 of 73,498
Next
